Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. (Q54393339)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

0 references

phosphorylation

0 references

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

author name string

Minhao Fan

1

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Jian Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Zhonghua Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Biyun Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Qunlin Zhang

5

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Chunlei Zheng

6

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Ting Li

7

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Chen Ni

8

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Zhenhua Wu

9

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Zhimin Shao

10

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Xichun Hu

11

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

language of work or name

0 references

publication date

1 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

143

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

1

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

141-151

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24292957

Global trends in breast cancer incidence and mortality 1973-1997.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Prognostic value of vascular endothelial growth factor in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

VEGF-targeted therapy: therapeutic potential and recent advances

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Phase II open-label study of sunitinib in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Cytokines and chemokines as regulators of angiogenesis in health and disease

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Pro-angiogenic cytokines and their role in tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Survivin expression quantified by Image Pro-Plus compared with visual assessment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Assessment of soluble angiogenic markers in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Optimization of multiplexed bead-based cytokine immunoassays for rat serum and brain tissue

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Biomarkers in tumor angiogenesis and anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2793-6

21 January 2018

Identifiers

10.1007/S10549-013-2793-6

1 reference

https://api.fatcat.wiki/v0/release/h3xksvyu5rcknkw5e3hq4bey7q

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_h3xksvyu5rcknkw5e3hq4bey7q

1 reference

https://api.fatcat.wiki/v0/release/h3xksvyu5rcknkw5e3hq4bey7q

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/h3xksvyu5rcknkw5e3hq4bey7q

30 July 2022

based on heuristic

mapped directly with Wikidata item

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54393339&oldid=2212450741"